JP Morgan Chase’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,494,183
| Closed | -$26.9M | – | 6029 |
|
|
2020
Q2 | $26.9M | Buy |
1,494,183
+1,442,634
| +2,799% | +$20.1M | 0.01% | 1189 |
|
|
2020
Q1 | $367K | Sell |
51,549
-117,208
| -69% | -$1.46M | ﹤0.01% | 3978 |
|
|
2019
Q4 | $4.03M | Buy |
168,757
+120,256
| +248% | +$3.32M | ﹤0.01% | 2854 |
|
|
2019
Q3 | $1.3M | Sell |
48,501
-619,731
| -93% | -$17.4M | ﹤0.01% | 3687 |
|
|
2019
Q2 | $17.8M | Sell |
668,232
-552,553
| -45% | -$17.3M | ﹤0.01% | 1651 |
|
|
2019
Q1 | $42.4M | Buy |
1,220,785
+500,330
| +69% | +$14.4M | 0.01% | 1037 |
|
|
2018
Q4 | $14.1M | Buy |
720,455
+34,376
| +5% | +$707K | ﹤0.01% | 1752 |
|
|
2018
Q3 | $18.3M | Buy |
686,079
+65,190
| +10% | +$2.13M | ﹤0.01% | 1734 |
|
|
2018
Q2 | $23.5M | Sell |
620,889
-49,385
| -7% | -$1.89M | ﹤0.01% | 1458 |
|
|
2018
Q1 | $21.9M | Buy |
670,274
+20,010
| +3% | +$878K | ﹤0.01% | 1441 |
|
|
2017
Q4 | $31.7M | Sell |
650,264
-94,438
| -13% | -$4.78M | 0.01% | 1243 |
|
|
2017
Q3 | $40.1M | Buy |
744,702
+26,544
| +4% | +$1.56M | 0.01% | 1062 |
|
|
2017
Q2 | $40.3M | Sell |
718,158
-346,034
| -33% | -$13.9M | 0.01% | 1026 |
|
|
2017
Q1 | $41.7M | Sell |
1,064,192
-181,728
| -15% | -$5.79M | 0.01% | 1025 |
|
|
2016
Q4 | $28M | Sell |
1,245,920
-18,235
| -1% | -$356K | 0.01% | 1249 |
|
|
2016
Q3 | $28.7M | Sell |
1,264,155
-48,033
| -4% | -$1.13M | 0.01% | 1138 |
|
|
2016
Q2 | $31M | Buy |
1,312,188
+14,072
| +1% | +$347K | 0.01% | 1095 |
|
|
2016
Q1 | $26.5M | Buy |
1,298,116
+526,817
| +68% | +$16.7M | 0.01% | 1156 |
|
|
2015
Q4 | $39.7M | Sell |
771,299
-149,106
| -16% | -$7.23M | 0.01% | 925 |
|
|
2015
Q3 | $39.2M | Sell |
920,405
-5,721
| -0.6% | -$276K | 0.01% | 900 |
|
|
2015
Q2 | $42.2M | Sell |
926,126
-21,212
| -2% | -$853K | 0.01% | 973 |
|
|
2015
Q1 | $36M | Sell |
947,338
-126,872
| -12% | -$4.36M | 0.01% | 1057 |
|
|
2014
Q4 | $30.4M | Sell |
1,074,210
-155,386
| -13% | -$4.32M | 0.01% | 1216 |
|
|
2014
Q3 | $31.1M | Sell |
1,229,596
-88,957
| -7% | -$2.34M | 0.01% | 1176 |
|
|
2014
Q2 | $38.5M | Sell |
1,318,553
-23,203
| -2% | -$562K | 0.01% | 983 |
|
|
2014
Q1 | $34.8M | Buy |
1,341,756
+300,323
| +29% | +$8.01M | 0.01% | 1010 |
|
|
2013
Q4 | $26.8M | Buy |
+1,041,433
| New | +$25.3M | 0.01% | 1158 |
|
JP Morgan Chase's PTLA Position: Q3 2020 in Review
JP Morgan Chase sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,494,183 shares — an estimated $26.9M sold.
JP Morgan Chase first reported a position in PTLA in Q4 2013 and held it in 27 quarters. The position peaked at $42.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- JP Morgan Chase reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- JP Morgan Chase sold 1,494,183 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $26.9M.
- JP Morgan Chase first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 27 quarters.
- JP Morgan Chase's Portola Pharmaceuticals, Inc. position peaked at $42.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on JP Morgan Chase's 13F filing for Q3 2020, filed 12 Nov 2020.